"Gathering momentum to control change" to meet new challenges and face the new future

2020 Hongqi Pharmaceutical Annual Work Conference and Annual Meeting was grandly held

On January 19, the 2020 Hongqi Pharmaceutical Annual Working Conference of "Gathering Power to Control Change" was held at the Wanda Vista Hotel in Shenyang.

Looking back on five years of hard work, the red flag is flourishing

Before the start of the conference, Hongqi Pharmaceutical’s "Five-Year Memorabilia Review VCR" was played on the big screen. From 2015 to 2019, Hongqi Pharmaceutical was determined to forge ahead, through continuous reform and innovation, in ensuring the supply of raw materials, upgrading and upgrading plants, and generic drugs. Significant development and major achievements have been made in consistency evaluation, product introduction, and social welfare activities. What is even more rare is that Red Flag people have the courage to assume social responsibilities. Since the launch of the "Double Thousand Action" in 2016, they have spent more than 4 million yuan in social welfare and sent care and care to more than 4,000 poor tuberculosis patients across the country.

In the past five years, Hongqi people have forged ahead and achieved outstanding results. This is the result of the hard work of the Hongqi management team and all employees, and it is worthy of the pride of Hongqi people!

Seeing the outstanding achievements and development of the company in the past five years, the employees also empathized with them and burst into applause. Amidst the applause, the 2020 Hongqi Pharmaceutical Annual Working Conference kicked off.

The real wealth and value of Talent Hongqi Pharmaceutical

"After reading this VCR, I feel a lot of emotion. It is these vivid faces that have created Hongqi's outstanding performance." Deputy General Manager Tong Guang said that "talents" are the real wealth and value of Hongqi Pharmaceutical.

At today's work conference, Hongqi Pharmaceutical took the first step in its talent strategy and vision in 2020. Deputy General Manager Tong Guang announced Hongqi Pharmaceutical's 2020 talent appointment decision.

From general manager to director, from department heads to workshop directors, the letter of appointment is a commendation for their work in the past year and a new expectation for the future.

After receiving the letter of appointment, the newly appointed leaders signed the assessment responsibility letter one by one with the general manager Yang Bo on the stage.

Replay 2019 Red Flag, Hundreds of Waters, Strive for Pioneer

Position is responsibility, pressure, and responsibility. Facing the 2020 assessment responsibility letter, the backbone of Hongqi have something to say:

● Chief Financial Officer Li Feng made a review of the theme of "Interpreting Company Operation from Financial Data"-in 2019, Hongqi completed an operating income of 415 million yuan, a net profit of 115 million yuan, and an operating cash flow of about 90 million yuan.

●Deputy General Manager and R&D Director Li Juan's speech entitled "Warming the Old and Meeting the New Knowledge"-In 2019, the R&D department has obtained three invention patents; in 2020, we must maintain integrity and innovate to help development, and forge ahead and seek new chapters.

● BD Director Liu Yazhou mentioned in "Exploring the Unknown to Boost Product Line Development" that the four keywords for the development of Hongqi's product line-the Chinese market, anti-tuberculosis drugs, leading brands, and professional and focused marketing.

●Miao Lan, Director of International Business, made a speech on "Working together to control the future-Firming Hongqi's internationalization path"-Hongqi's strategic positioning in 2020 is to deepen the tuberculosis field and create a world-class anti-tuberculosis drug pharmaceutical company!

●Feng Lijun, deputy director of production, mentioned in "Lean Management Endogenous Empowerment"-in 2019, all Red Flag people completed the annual output of 1.122 billion pieces, achieving an output value of 218 million yuan, a pass rate of 100%, and a planned completion rate of 100%. Meet market sales.

●Quality Director Xu Linlin reviewed in "Breakthrough and Improve Deep Compliance"-our QC completed the inspection task in 2019. In the group audit, the quality system score has improved compared with the previous year.

● Marketing Director Xing Dan mentioned in his speech entitled "New Situation and New Chapter"-Red Flag's marketing strategy in 2020 is to analyze the environment, analyze itself, analyze products, and base on products. Relying on wisdom to lead, so as to plan for the future market layout.

● Liang Jing, director of the human resources department, expressed in "Hongqi's Future-oriented Organizational Capability Exploration-Being an HR that Drives Organizational Growth"-In 2020, the company must build an incentive mechanism that supports strategic development. The purpose is to allow truly outstanding employees to take advantage of To more pay.

The keynote speeches of the company not only let all the Hongqi people understand the company's performance, growth, and shortcomings last year, but also succinctly explained a series of major changes that the company will face in 2020.

In this regard, the leadership of the group and the company fully affirmed and gave deep expectations for the future.

Hope to "build up momentum to control change" to meet new challenges and meet a new future

Yang Bo, General Manager of Shenyang Hongqi Pharmaceutical:

The overall development of Hongqi has achieved gratifying results, and 2020 will face new challenges and new development opportunities. At the new height and platform, Hongqi Pharmaceutical has also entered a new development channel.

Accumulating momentum, accumulating the advantages and results achieved in 2019. From the support system that relies on human and financial resources to the security system to improve market competitiveness, we must focus on anti-tuberculosis drugs at the strategic level to achieve expansion in the urinary field; at the institutional level, we must complete the system iteration and maintain the bottom line of compliance; at the process level, we must focus on anti-tuberculosis drugs. Continue to optimize and sort to ensure that the process is fast and efficient; from the training system, employee training must keep up with the development of the enterprise and keep up with the development of the times.

"I believe that Hongqi can do a good job in the market, and I believe that Hongqi people have a better future!"

Li Jianqing, Senior Assistant to the President of Fosun Pharma, Senior Vice President of Industrial Company

Li Jianqing, senior assistant to the president of Fosun Pharma and senior vice president of the industrial company:

Hongqi's sales exceeded 400 million yuan, and its profit exceeded 100 million yuan for the first time. Hongqi entered the billion yuan club. It is inseparable from the hard work of everyone here. Everyone has worked hard. It is worth congratulating! In today's report, all departments not only have bright spots, but also do not avoid problems. They have a very sincere attitude. If everyone finds the source of the problem, they will be improved. From the group level, we do have shortcomings, which are still very big. But from another perspective, this is also the space for our development. If the future red flags want to be themselves, they cannot have any illusions. If Hongqi wants to take the international route, it must adapt to the new management and control model, from passive supervision to active awareness.

"In 2020, everyone will do their best to be the greatest support and support for the company!

Wu Yifang, President and CEO of Fosun Pharma, Chairman of Fosun Pharmaceutical Industry Company, Chairman of Shenyang Hongqi Pharmaceutical

Wu Yifang, President and CEO of Fosun Pharma, Chairman of Fosun Pharmaceutical Industry Company, and Chairman of Shenyang Hongqi Pharmaceutical:

First of all, on behalf of Fosun Pharma’s Chairman Chen Qiyu and Co-Chairman Yao Fang, congratulations on the achievements of Hongqi Pharmaceutical in 2019.

2019 is really not easy. Through hard work, our red flag has a profit of more than 100 million yuan, reaching a net profit of 115 million yuan. We have reached a new level. We must congratulate if we have any achievements: 2019, red flag, congratulations!

In the past five years, Hongqi has experienced many winds and rains, traversed many dangerous beaches, and experienced the risks and trials of rivers and lakes. Even so difficult, Hongqi still survives and develops tenaciously, making progress year by year. As the management, our mission is to develop the red flag well and make the "red flag" more colorful, flying in China and in the world; it is to let employees experience the stable and upward career development opportunities brought about by the prosperity of the company. Pride.

In 2019, the red flag has been realized-with money in hand, business outside, and team underneath, this is the structure of a healthy company.

In the future, I hope that Hongqi will be willing to invest in attracting and cultivating people, and reflect its own achievements and value. I hope everyone will use the spirit of not forgetting the original intention and lift up the "potential" of the red flag!

"One year has passed, I would like to extend my warmest greetings to all the management team and employees. You have worked hard, thank you!"

The leaders' enthusiastic and sincere speeches were praised and supported by all employees of Hongqi.

After the 2020 work conference, it was the Spring Festival Gala, in which the outstanding teams and individuals in 2019 were commended. At the same time, the employees also brought a variety of cultural programs, and a variety of lucky draws and red envelope rain were set up on the scene.

In a prosperous atmosphere, the 2020 Hongqi Pharmaceutical Annual Working Conference and the New Year Gala came to a successful conclusion. Hongqi people stand on the new starting point created in the past five years and enter a new stage and stage in 2020, opening a new chapter in the development of Hongqi Pharmaceutical.